Skip to content

DSDM PHARMA

Active Private limited companyfounded 2008active for 18 yearsBeekstraat 145, 9031 GhentKBO/BCE: BE 0894.719.585

Lifetime

18 annual accounts with figures on one time axis
peak of €374,448 in 2025
€374,448▲ 112%
peak of €211,084 in 2025
€211,084▲ 583%
peak of €635,891 in 2025
€635,891▲ 49.7%
€1.0m▼ 37.3%
peak of 0 FTE in 2022
0 FTE 
Board2 names since 2008
2 directors and 1 other
Documentsfilings and deeds
30-09-202661 days late
2025abbreviated format
Gross margin from €176,742 to €374,448Result from €30,886 to €211,084Equity from €424,806 to €635,891Debts from €1.6m to €1.0mCash from €43,664 to €30,149

Key points

from the 2025 annual accounts

Equity

€635,891 ▲ 49.7%

DSDM PHARMA has made a profit in every financial year since 2008.

Result

€211,084 ▲ 583%
€30,9002024€211,0002025

The result rose in 2025 from €30,886 to €211,084.

Turnover

≈ €570,000 estimated

The abbreviated format states no turnover.

Liquidity

1.94 was 0.38 in 2024

Short-term debts rose from €197,609 to €202,455.

Filings

18 annual accounts 61 days
AprilJune31 JulyOctober2010201520202025

Latest accounts filed late: after the legal deadline.

Position in the sector

€374,448

Higher gross margin than 80% of companies in head offices and management consultancy. The sector median is €97,219, over 10,654 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 17,817 companies had the same profile as DSDM PHARMA has now. Each dot stands for 45 companies, two years later.

96.5%
were still trading
3.2%
stopped another way
0.3%
went bankrupt
  • Small
  • 10 to 20 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,994 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 17,817 companies, not a prediction for DSDM PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 03-01-2008
Director, since 03-01-2008

Shares in 1 company,

Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0894719585
Environmental permit granted Facade, roof or renovation · decided by Ghent
(director) and (director) change roles General meeting of 30-12-2023 · Gazette deed
Incorporation published on 16-01-2008 · Gazette deed
All 29 events

Comparable companies

same main activity, similar in size and age
Company
DSDM PHARMA Ghent €1.6m €374,448 38.7% 0
VGF INVEST & CONSULTING Hamme (Vl.) €1.5m €439,980 67.5% 0
STEMAN Stekene €1.7m €313,601 75.2% 0
PATRICK DE GREVE Sint-Martens-Latem €1.4m €315,713 89.6% 0
DV-COM Heers €1.8m €364,979 85.0% 0
RHG Leuven €1.4m €348,831 82.9% 0
AJW Ottignies-Louvain-la-Neuve €1.5m €326,814 50.3% 0

These companies have the same main activity as DSDM PHARMA: business and other management consultancy (NACE 70200). They are comparable in size and age: total assets between €1.4m and €1.8m, founded between 2007 and 2010.

Official details

Source: KBO
Status
Active since 08-01-2008Normal situation
Activity
Business and other management consultancyNACE 70200and 1 other
Establishment unit
2.284.119.5749031 Ghent, since 08-01-2008
Financial year end
31 December
Peppol
Reachable since 23-11-2025
Company details

Annual accounts 2025

€1.6m▼ 19.2%
Filing
Filed on 30-09-2026
Financials

Insights on DSDM PHARMA

DSDM PHARMA files the abbreviated format. That format states no turnover. The gross margin rose from €40,142 in 2008 to €374,448 in 2025.

The balance sheet grew most from 2022 to 2024 through fixed assets, financed with long-term debt.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about DSDM PHARMA

What is the company number of DSDM PHARMA?
The company number of DSDM PHARMA is 0894.719.585. The VAT number is the same number with BE in front: BE 0894.719.585.
Where is DSDM PHARMA based?
The registered office is at Beekstraat 145, 9031 Ghent.Company details
What does DSDM PHARMA do?
According to the KBO register, the main activity is business and other management consultancy (NACE 70200).
What is the legal form of DSDM PHARMA?
DSDM PHARMA is a private limited company (BV).
When was DSDM PHARMA founded?
DSDM PHARMA was founded on 08-01-2008.
Is DSDM PHARMA still active?
Yes, DSDM PHARMA is an active enterprise in the KBO register.
What is the turnover of DSDM PHARMA?
The turnover in financial year 2025 is about €570,000. This figure is estimated from the gross margin of €374,448 and 72 comparable companies (NACE 70200). It probably lies between €440,000 and €1.0m.Financials
Is DSDM PHARMA profitable?
In financial year 2025, DSDM PHARMA made a profit of €211,084.
Where can I find the annual accounts of DSDM PHARMA?
DSDM PHARMA filed 18 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of DSDM PHARMA due?
DSDM PHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.